share_log

和黃醫藥：自願性公告 - 和黃醫藥宣佈與恆瑞醫藥達成合作並啟動索凡替尼(surufatinib)聯合卡瑞利珠單抗(camrelizumab)用於治療初治胰腺導管腺癌的II/III期研究

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

Hong Kong Stock Exchange ·  May 14 08:00
Summary by Futu AI
和黃醫藥（HUTCHMED）宣布與江蘇恆瑞醫藥股份有限公司（恆瑞醫藥）合作，啟動針對初治胰腺導管腺癌的II/III期臨床試驗。該試驗將評估和黃醫藥的索凡替尼與恆瑞醫藥的PD-1抗體卡瑞利珠單抗、白蛋白結合型紫杉醇和吉西他濱的聯合療法。首名受試者已於2024年5月8日接受治療。該研究是多中心、隨機、開放標籤、陽性對照的，旨在評估新聯合療法對成人轉移性胰臟癌患者的療效和安全性。研究將招募約500名患者，主要終點為總生存期。和黃醫藥首席執行官兼首席科學官蘇慰國博士表示，希望這項合作能為患者帶來創新治療選擇。索凡替尼在中國市場已以蘇泰達®上市，卡瑞利珠單抗在中國獲批多個適應症，並已納入醫保藥品目錄。
和黃醫藥（HUTCHMED）宣布與江蘇恆瑞醫藥股份有限公司（恆瑞醫藥）合作，啟動針對初治胰腺導管腺癌的II/III期臨床試驗。該試驗將評估和黃醫藥的索凡替尼與恆瑞醫藥的PD-1抗體卡瑞利珠單抗、白蛋白結合型紫杉醇和吉西他濱的聯合療法。首名受試者已於2024年5月8日接受治療。該研究是多中心、隨機、開放標籤、陽性對照的，旨在評估新聯合療法對成人轉移性胰臟癌患者的療效和安全性。研究將招募約500名患者，主要終點為總生存期。和黃醫藥首席執行官兼首席科學官蘇慰國博士表示，希望這項合作能為患者帶來創新治療選擇。索凡替尼在中國市場已以蘇泰達®上市，卡瑞利珠單抗在中國獲批多個適應症，並已納入醫保藥品目錄。
HUTCHMED ANNOUNCED A COLLABORATION WITH JIANGSU HENRI PHARMACEUTICAL CO., LTD. (HENRI PHARMACEUTICALS) TO LAUNCH PHASE II/III CLINICAL TRIALS FOR INITIATING PANCREATIC DUCT CANCER. The trial will evaluate the combined treatment of Xanthinic and Hengrei's PD-1 antibody, Carrilobulmonal, protein-bound retinol, and Gizitabamine. The first participant received treatment on May 8, 2024. The multi-center, randomized, open-label, positive-controlled study was designed to evaluate the efficacy and safety of the new combination therapy in patients with metastatic pancreatic cancer in adults. The study will recruit about 500 patients, with the primary endpoint being total survival. Dr. Su Ju-guo, CEO and Chief Scientific Officer of Wah Wong Pharmaceuticals, said he hoped the collaboration could bring innovative treatment options to patients. SOFANTINE HAS BEEN LISTED ON THE CHINESE MARKET AS SUTEDA®, CARILIZU HAS BEEN APPROVED FOR MULTIPLE INDICATIONS IN CHINA AND HAS BEEN INCLUDED IN THE PHARMACEUTICAL CATALOGUE.
HUTCHMED ANNOUNCED A COLLABORATION WITH JIANGSU HENRI PHARMACEUTICAL CO., LTD. (HENRI PHARMACEUTICALS) TO LAUNCH PHASE II/III CLINICAL TRIALS FOR INITIATING PANCREATIC DUCT CANCER. The trial will evaluate the combined treatment of Xanthinic and Hengrei's PD-1 antibody, Carrilobulmonal, protein-bound retinol, and Gizitabamine. The first participant received treatment on May 8, 2024. The multi-center, randomized, open-label, positive-controlled study was designed to evaluate the efficacy and safety of the new combination therapy in patients with metastatic pancreatic cancer in adults. The study will recruit about 500 patients, with the primary endpoint being total survival. Dr. Su Ju-guo, CEO and Chief Scientific Officer of Wah Wong Pharmaceuticals, said he hoped the collaboration could bring innovative treatment options to patients. SOFANTINE HAS BEEN LISTED ON THE CHINESE MARKET AS SUTEDA®, CARILIZU HAS BEEN APPROVED FOR MULTIPLE INDICATIONS IN CHINA AND HAS BEEN INCLUDED IN THE PHARMACEUTICAL CATALOGUE.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.